JPLA
LXRX icon

Joseph P. Lucia & Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History

Joseph P. Lucia & Associates’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$3K – 591
2020
Q4 		$3K Buy
+1,000
New +$1.91K ﹤0.01% 426

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joseph P. Lucia & Associates's LXRX Position: Q1 2021 in Review

Joseph P. Lucia & Associates sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 1,000 shares — an estimated $3K sold.

Joseph P. Lucia & Associates first reported a position in LXRX in Q4 2020 and held it in 1 quarter. The position peaked at $3K in Q4 2020. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

  • Joseph P. Lucia & Associates reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 1,000 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $3K.
  • Joseph P. Lucia & Associates first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Joseph P. Lucia & Associates's Lexicon Pharmaceuticals position peaked at $3K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Joseph P. Lucia & Associates's 13F filing for Q1 2021, filed 23 Apr 2021.